Table 4. Hazard/Subhazard ratio of outcomes in statin users in comparison to nonusers.

Outcome	Hazard ratio	95% confidence interval	p-value
Secondary analysis
Propensity score matched cohort (81,146 statin users and 81,146 nonusers)
Incident CKD	1.20	1.16–1.25	<0.001
Incident Diabetes with ophthalmic manifestations	1.35	1.26–1.44	<0.001
Incident Diabetes with neurological manifestations	1.19	1.15–1.24	<0.001
Propensity score matched cohort with death as a competing risk factor (81,146 statin users and 81,146 nonusers)
Incident CKD	1.13*	1.09–1.17	<0.001
Incident Diabetes with ophthalmic manifestations	1.28*	1.20–1.37	<0.001
Incident Diabetes with neurological manifestations	1.19*	1.15–1.24	<0.001
Post-Hoc analysis
Intensive cholesterol lowering statin users in comparison to nonusers in the overall cohort with death as a competing risk factor (38,823 statin users and 110,195 active comparators)
Incident CKD	1.57*	1.51–1.64	<0.001
Incident Diabetes with ophthalmic manifestations	1.71*	1.59–1.83	<0.001
Incident Diabetes with neurological manifestations	1.30*	1.24–1.36	<0.001

*Subhazard ratio